What Is Redemplo? As the world-first APOC3 siRNA therapy, Redemplo® represents a significant advancement in RNA interference (RNAi)-based precision medicine
In recent years, Antibody-Drug Conjugates (ADCs) have emerged as one of the fastest-growing classes of innovative cancer therapies, combining the
In recent years, Antibody-Drug Conjugates (ADCs) have continued to drive advances in precision oncology, gradually becoming one of the most
On August 11, 2026, Enhertu® (generic name: trastuzumab deruxtecan, T-DXd) in combination with Pertuzumab was approved in China for the
Tezepelumab Injection is a targeted biologic therapy that blocks TSLP to help control airway inflammation. On August 17, 2026, AstraZeneca
The 10 breakthrough drugs to watch in H2 2026 in China span a wide range of therapeutic areas, including oncology,
HER2 Bispecific Antibody Meets China’s PD-1: In August 2026, the U.S. Food and Drug Administration (FDA) approved two first-line treatment
On August 27, 2026, a major milestone was reached in the field of psoriasis treatment in China. Johnson & Johnson
New breakthrough in long-acting RSV monoclonal antibodies: XinDuoTuo® and YingMuLe® approved on the same day. On September 3, 2026, China’s
Lecankitug Injection receives NMPA approval. On August 27, 2026, Livzon Pharmaceutical Group Inc. announced that its holding subsidiary, Livzon Biologics
